| 货号 | 45010S |
| 反应种属 | Human\Mouse\Moneky |
| 来源宿主 | Rabbit |
| 应用 | WB, IP |
| 目标/特异性 | TET2 Antibody recognizes endogenous levels of total TET2 protein. This antibody detects bands of unknown identity at 100, 130, and 160 kDa. |
| 使用方法 | W IP |
| 供应商 | CST |
| 灵敏度 | Endogenous |
| 背景 | Methylation of DNA at cytosine residues is a heritable, epigenetic modification that is critical for proper regulation of gene expression, genomic imprinting, and mammalian development (1,2). 5-methylcytosine is a repressive epigenetic mark established de novo by two enzymes, DNMT3a and DNMT3b, and is maintained by DNMT1 (3, 4). 5-methylcytosine was originally thought to be passively depleted during DNA replication. However, subsequent studies have shown that Ten-Eleven Translocation (TET) proteins TET1, TET2, and TET3 can catalyze the oxidation of methylated cytosine to 5-hydroxymethylcytosine (5-hmC) (5). Additionally, TET proteins can further oxidize 5-hmC to form 5-formylcytosine (5-fC) and 5-carboxylcytosine (5-caC), both of which are excised by thymine-DNA glycosylase (TDG), effectively linking cytosine oxidation to the base excision repair pathway and supporting active cytosine demethylation (6,7). TET2 is the most frequently mutated gene in myeloid dysplastic syndrome (MDS), a dysplasia of myeloid, megakaryocytic, and/or erythroid cell lineages, of which 30% progress to acute myeloid leukemia (AML) (8, 9). It is also mutated in diffuse large B-cell lymphoma (10). TET2 protein expression is often reduced in solid tumors such as prostate cancer, melanoma, and oral squamous cell carcinoma (11-13). |
| 存放说明 | -20C |
| 计算分子量 | 280 |
| 参考文献 | 1 . Hermann, A. et al. (2004) Cell Mol Life Sci 61, 2571-87. 2 . Turek-Plewa, J. and Jagodziński, P.P. (2005) Cell Mol Biol Lett 10, 631-47. 3 . Okano, M. et al. (1999) Cell 99, 247-57. 4 . Li, E. et al. (1992) Cell 69, 915-26. 5 . Tahiliani, M. et al. (2009) Science 324, 930-5. 6 . He, Y.F. et al. (2011) Science 333, 1303-7. 7 . Ito, S. et al. (2011) Science 333, 1300-3. 8 . Langemeijer, S.M. et al. (2009) Nat Genet 41, 838-42. 9 . Yamazaki, J. et al. (2012) Epigenetics 7, 201-7. 10 . Asmar, F. et al. (2013) Haematologica 98, 1912-20. 11 . Nickerson, M.L. et al. (2013) Hum Mutat 34, 1231-41. 12 . Lian, C.G. et al. (2012) Cell 150, 1135-46. 13 . Jäwert, F. et al. (2013) Anticancer Res 33, 4325-8. |
Western blot analysis of extracts from various cell lines using TET2 Antibody. | |
Western blot analysis of extracts from TET2 wild-type (WT) and knockout (KO) 293T cell lines using TET2 Antibody (upper) and α-Actinin (D6F6) XP® Rabbit mAb #6487 (lower). | |
Western blot analysis of extracts from F9 and NIH/3T3 cell lines using TET2 Antibody (upper) and α-Actinin (D6F6) XP® Rabbit mAb #6487 (lower). As expected, NIH/3T3 cells are negative for TET2 expression. |
